Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: An indication of viral fitness?

Journal of Virology

Volumn 77, Issue 17, 2003, Pages 9422-9430

  De Oliveira, Tulio ^a   Engelbrecht, Susan ^b   Van Rensburg, Estrelita Janse ^b   Gordon, Michelle ^a   Bishop, Karen ^a   Zur Megede, Jan ^c   Barnett, Susan W ^c   Cassol, Sharon ^a,d  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; NEF PROTEIN; POL PROTEIN; PROTEINASE;

ADAPTATION; ARTICLE; ENZYME POLYMORPHISM; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; UNINDEXED SEQUENCE; VIRION;

AMINO ACID SEQUENCE; BINDING SITES; EVOLUTION, MOLECULAR; FUSION PROTEINS, GAG-POL; GENE PRODUCTS, GAG; GENES, GAG; GENES, POL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; PHYLOGENY; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 0041888278     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.17.9422-9430.2003     Document Type: Article

References (49)

1. Anisimova, M., J. P. Bielawski, and Z. Yang. 2001. Accuracy and power of the likelihood ratio test in detecting adaptive molecular evolution. Mol. Biol. Evol. 18:1585-1592.
2. Ball, S. C., A. Abraha, K. R. Collins, A. J. Marozsan, H. Baird, M. E. Quinones-Mateu, A. Penn-Nicholson, M. Murray, N. Richard, M. Lobritz, P. A. Zimmerman, T. Kawamura, A. Blauvelt, and E. J. Arts. 2003. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J. Virol. 77:1021-1038.
3. Billich, S., M. T. Knoop, J. Hansen, P. Strop, J. Sedlacek, R. Mertz, and K. Moelling. 1988. Synthetic peptides as substrates and inhibitors of human immunodeficiency virus-1 protease. J. Biol. Chem. 263:17905-17908.
4. Brindeiro, R., B. Vanderborght, F. Caride, L. Correa, R. M. Oravec, O. Berro, L. Stuyver, and A. Tanuri. 1999. Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from Brazilian untreated individuals. Antimicrob. Agents Chemother. 43:1674-1680.
5. Cote, H. C. F., Z. L. Brumme, and P. R. Harrigan. 2001. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75:589-594.
6. Croteau, G., L. Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71:1089-1096.
7. De Oliveira, T., R. Miller, M. Tarin, and S. Cassol. 2002. An integrated Genetic Data Environment (GDE)-based LINUX interface for the analysis of HIV-1 and other microbial sequences. Bioinformatics 19:1-2.
8. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3736-3769.
9. Ericson-Viitanen, S., J. Manfredi, P. Viitanen, D. E. Tribe, R. Tritch, C. A. Hutchison III, D. D. Loeb, and R. Swanstrom. 1989. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res. Hum. Retrovir. 5:577-591.
10. Esparza, J., and N. Bhamarapravati. 2000. Accelerating the development and future availability of HIV-1 vaccines: why, when, where and how? Lancet 355:2061-2066.
11. Gao, F., D. L. Robertson, C. D. Carruthers, S. G. Morrison, B. Jian, Y. Chen, F. Barre-Sinoussi, M. Girard, A. Srinivasan, A. G. Abimiku, G. M. Shaw, P. M. Sharp, and B. Hahn. 1998. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J. Virol. 72:5680-5698.
12. Gonzales, L. J. M., R. M. Brindeiro, M. Gordon, A. Calazans, M. A. Soares, S. Cassol, and A. Tanuri. The subtype C of human immunodeficiency virus type 1 circulating in Brazil and South Africa presents a hypersusceptibility to the protease inhibitor Lopinavir. J. Antimicrob. Chemother. in press.
13. Gordon, M., T. De Oliveira, K. Bishop, H. M. Coovadia, L. Madurai, S. Engelbrecht, E. Janse van Rensburg, A. Mosam, and S. Cassol. 2003. Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies. J. Virol. 77:2587-2599.
14. Ikuta, K., S. Suzuki, H. Horikoshi, T. Mukai, and R. B. Luftig. 2000. Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis. Microbiol. Mol. Biol. Rev. 64:725-745.
15. Jacks, T., M. D. Power, F. R. Masiarz, P. A. Luciw, P. J. Barr, H. E. Varmus. 1998. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331:280-283.
16. Kaplan, A. H., M. Manchester, and R. Swanstrom. 1994. The activity of the protease of HIV-1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol. 68:6782-6786.
17. Krausslich, H., F. H. Ingraham, M. Skoog, E. Wimmer, P. V. Pallai, and C. A. Carter. 1989. Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc. Natl. Acad. Sci. USA 86:807-811.
18. Kuiken, C., B. Foley, B. H. Hahn, P. Marx, F. E. McCutchan, J. Mellors, J. Mullins, J. Sodroski, S. Wolinsky, and B. Korber. 2002. HIV sequence compendium. Los Alamos National Laboratory, Los Alamos, N.Mex.
19. Little, S. J. 2000. Transmission and prevalence of HIV resistance among treatment-naïve subjects. Antivir. Ther. 5:33-40.
20. McCormick-Davis, C., S. B. Dalton, D. K. Singh, and E. B. Stephens. 2000. Comparisons of Vpu sequences from diverse geographical isolates of HIV type 1 identifies the presence of highly variable domains, additional invariant amino acids and a signature sequence motif common to subtype C isolates. AIDS Res. Hum. Retrovir. 16:1089-1095.
21. Muller, B., T. Patschinsky, and H. G. Krausslich. 2002. The late-domain-containing protein p6 is the predominant phosphoprotein of human immunodeficiency virus type 1 particles. J. Virol. 76:1015-1024.
22. Novitsky, V. A., M. A. Montano, M. F. McLane, B. Renjifo, F. Vannberg, B. T. Foley, T. P. Ndung'u, M. Rahman, M. J. Makhema, R. Marlink, and M. Essex. 1999. Molecular cloning and phylogenetic analysis of human immunodeficiency virus type 1 subtype C: a set of 23 full-length clones from Botswana. J. Virol. 73:4427-4432.
23. Peeters, M., R. Vincent, J. L. Perret, M. Lasky, D. Patrel, F. Liegeois, V. Courgnaud, R. Seng, T. Matton, S. Molinier, and E. Delaporte. 1999. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20:115-121.
24. Pettit, S. C., S. Gulnik, L. Everitt, and A. H. Kaplan. 2003. The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage. J. Virol. 77:366-374.
25. Pettit, S. C., G. J. Henderson, C. A. Schiffer, and R. Swanstrom. 2002. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by viral protease. J. Virol. 76:10226-10233.
26. Pettit, S. C., M. D. Moody, R. S. Wehbie, A. H. Kaplan, P. V. Nantermet, C. A. Klein, and R. Swanstrom. 1994. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68:8017-8027.
27. Ping, L. H., J. A. Nelson, I. F. Hoffman, J. Schock, S. L. Lamers, M. Goodman, P. Vernazza, P. Kazembe, M. Maida, D. Zimba, M. M. Goodenow, J. J. Eron, Jr., S. A. Fiscus, M. S. Cohen, and R. Swanstrom. 1999. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J. Virol. 73:6271-6281.
28. Rambaut, A. 2000. Estimating the rate of molecular evolution: incorporating non-contemporaneous sequences into maximum likelihood phylogenetics. Bioinformatics 16:395-399.
29. Ridky, T. W., C. E. Cameron, J. Cameron, J. Leis, T. Copeland, A. Wlodawer, I. T. Weber, and R. W. Harrison. 1996. Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids in adjacent enzyme subsites. J. Biol. Chem. 271:4709-4717.
30. Rodenburg, C. M., Y. Li, and S. A. Trask. 2001. Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res. Hum. Retrovir. 17:161-168.
31. Shankarappa, R., R. Chatterjee, and C. Learn. 2001. Human immunodeficiency virus type 1 env sequences from Calcutta in eastern India: identification of features that distinguish subtype C sequences in India from other subtype C sequences. J. Virol. 75:10479-10487.
32. Shehu-Xhilaga, M., H. G. Kraesslich, S. Pettit, R. Swanstrom, J. Y. Lee, J. A. Marshall, S. M. Crowe, and J. Mak. 2001. Proteolytic processing of the p2/nucleocapsid cleavage site is critical for human immunodeficiency virus type 1 RNA dimer maturation. J. Virol. 75:9156-9164.
33. Smith, S. W., R. Overbeek, C. R., Woese, W. Gilbert, and P. M. Gillevet. 1994. The Genetic Data Environment: an expandable GUI for multiple sequence analysis. Comput. Appl. Sci. 10:671-675.
34. Soares, M. A., T. De Oliveira, R. M. Brindeiro, R. S. Diaz, E. C. Sabino, L. Brigido, I. L. Pires, M. G. Morgado, M. C. Dantas, D. Barreira, P. R. Teixeira, S. Cassol, A. Tanuri, and the Brazilian Network for Drug Resistance Surveillance. 2003. A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil. AIDS 17:1-11.
35. Swanstrom, R., and J. W. Wills. 1997. Retroviral gene expression. II. Synthesis, processing, and assembly of viral proteins, p. 263-334. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor. Laboratory, Cold Spring Harbor, N.Y.
36. Tatt, I. D., K. L. Barlow, A. Nicoll, and J. P. Clewley. 2001. The public health significance of HIV-1 subtypes. AIDS 15:S59-S71.
37. Tessmer, U., and H.-G. Karausslich. 1998. Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity. J. Virol. 72:3459-3463.
38. Thomas, E. K., R. J. Connelly, S. Pennathur, L. Dubrovsky, O. K. Haffar, and M. I. Bukrinsky. 1996. Anti-idiotypic antibody to the V3 domain of gp120 binds to vimentin: a possible role of intermediate filaments in the early steps of HIV-1 infection cycle. Viral Immunol. 9:73-87.
39. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignments through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
40. Tomasselli, A. G., and R. L. Heinrickson. 1994. Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates. Methods Enzymol. 241:279-301.
41. Tozser, J., P. Bagossi, P. Boross, J. M. Louis, E. Majerova, S. Oroszlan, and T. D. Copeland. 1999. Effect of serine and tyrosine phosphorylation on retroviral proteinase substrates. Eur. J. Biochem. 265:423-429.
42. Van Harmelen, J. H., E. Van der Ryst, and S. A. Loubser. 1999. A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. AIDS Res. Hum. Retrovir. 15:395-398.
43. Velazquez-Campoy, A., M. J. Todd, S. Vega, and E. Freire. 2001. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc. Natl. Acad. Sci. USA 98:6062-6067.
44. Yang, Z. 2000. Maximum likelihood estimation on large phylogenies and analysis of adaptive evolution in human influenza virus A. J. Mol. Evol. 51:423-432.
45. Yang, Z., R. Nielsen, N. Goldman, and A.-M. K. Pedersen. 2000. Codon-substitution models for variable selection pressure at amino acid sites. Genetics 155:431-449.
46. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306.
47. Zhang, Y. M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.
48. Zur Megede, J., S. Engelbrecht, T. De Oliveira, S. Cassol, T. J. Scriba, E. Janse van Rensburg, and S. W. Barnett. 2002. Novel evolutionary analyses of full-length HIV-1 subtype C molecular clones from Cape Town, South Africa. AIDS Res. Hum. Retrovir. 18:1327-1332.
49. Zybarth, G., and C. Carter. 1995. Domains upstream of the protease (PR) in human immunodeficiency virus type I Gag-Pol influence PR autoprocessing. J. Virol. 69:3878-3884.